Literature DB >> 3532391

The antibody crossmatch in liver transplantation.

R D Gordon, J J Fung, B Markus, I Fox, S Iwatsuki, C O Esquivel, A Tzakis, S Todo, T E Starzl.   

Abstract

Six hundred sixty-seven first, second, and third orthotopic liver allografts in 520 patients were reviewed to determine the effect of recipient panel-reactive antibody (PRA) and donor-recipient antibody crossmatch on 2-year patient and liver allograft survival rates. Neither a high panel-reactive antibody nor a positive crossmatch for donor-specific preformed antibody was associated with decreased patient or liver allograft survival for primary grafts or retransplants. Two patients have been given kidney transplants immediately after a liver allograft from a donor with whom each patient had an initial strongly positive donor-specific antibody crossmatch. The liver apparently removed or neutralized circulating anti-donor antibody, since the renal allografts functioned promptly and did not experience hyperacute rejection.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3532391      PMCID： PMC3095820     

Source DB:  PubMed          Journal:  Surgery        ISSN： 0039-6060            Impact factor:   3.982


  7 in total

Review 1.  Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction.

Authors:  T E Starzl; M Ishikawa; C W Putnam; K A Porter; R Picache; B S Husberg; C G Halgrimson; G Schroter
Journal:  Transplant Proc       Date:  1974-12       Impact factor: 1.066

2.  Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells.

Authors:  F Kissmeyer-Nielsen; S Olsen; V P Petersen; O Fjeldborg
Journal:  Lancet       Date:  1966-09-24       Impact factor: 79.321

3.  Significance of the positive crossmatch test in kidney transplantation.

Authors:  R Patel; P I Terasaki
Journal:  N Engl J Med       Date:  1969-04-03       Impact factor: 91.245

4.  The lymphocytotoxic crossmatch test in clinical renal transplantation.

Authors:  A Ting
Journal:  Transplantation       Date:  1983-05       Impact factor: 4.939

5.  Liver transplantation against T cell-positive warm crossmatches.

Authors:  S Iwatsuki; B S Rabin; B W Shaw; T E Starzl
Journal:  Transplant Proc       Date:  1984-12       Impact factor: 1.066

6.  Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection.

Authors:  J J Fung; A J Demetris; K A Porter; S Iwatsuki; R D Gordon; C O Esquivel; R Jaffe; A Tzakis; B W Shaw; T E Starzl
Journal:  Nephron       Date:  1987       Impact factor: 2.847

7.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640
  7 in total
  36 in total

1.  Association of HLA Compatibility and Decreased Liver Transplant Survival.

Authors:  B H Markus; R J Duquesnoy; R D Gordon; J J Fung; M Vanek; G Klintmalm; C Bryan; D Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

2.  Antibody mediated rejection of human liver allografts: transplantation across ABO blood group barriers.

Authors:  A J Demetris; R Jaffe; A Tzakis; G Ramsey; S Todo; S Belle; C Esquivel; R Shapiro; A Zjako; B Markus
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

3.  Transplantation.

Authors:  T E Starzl
Journal:  JAMA       Date:  1989-05-19       Impact factor: 56.272

4.  Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy.

Authors:  S Takaya; R Duquesnoy; Y Iwaki; J Demetris; A Yagihashi; O Bronsther; S Iwatsuki; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

5.  High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant.

Authors:  J G O'Leary; H Kaneku; B M Susskind; L W Jennings; M A Neri; G L Davis; G B Klintmalm; P I Terasaki
Journal:  Am J Transplant       Date:  2011-06-14       Impact factor: 8.086

6.  Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch.

Authors:  H R Doyle; I R Marino; F Morelli; C Doria; L Aldrighetti; J McMichael; J Martell; T Gayowski; T E Starzl
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

Review 7.  What's new in clinical solid organ transplantation by 2013.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2014-12-24

8.  Potential various appearances of hyperacute rejection in human liver transplantation.

Authors:  G Gubernatis; J Kemnitz; A Bornscheuer; E R Kuse; R Pichlmayr
Journal:  Langenbecks Arch Chir       Date:  1989

9.  Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury.

Authors:  S Kakizoe; K Yanaga; T E Starzl; A J Demetris
Journal:  Hepatology       Date:  1990-06       Impact factor: 17.425

10.  Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies.

Authors:  S L Saidman; R J Duquesnoy; A J Demetris; J McCauley; H Ramos; G Mazariegos; R Shapiro; T E Starzl; J J Fung
Journal:  Transpl Immunol       Date:  1994       Impact factor: 1.708
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.